{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:01:37Z","timestamp":1783645297023,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6931,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001]]},"DOI":"10.1093\/annonc\/12.suppl_2.s47","type":"journal-article","created":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T01:58:19Z","timestamp":1327024699000},"page":"S47-S50","source":"Crossref","is-referenced-by-count":45,"special_numbering":"S2","title":["The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours"],"prefix":"10.1016","volume":"12","author":[{"given":"G.A.","family":"Kaltsas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000201211","article-title":"Management of gastroenteropancreatic endocrine tumours: The place of somatostatin analogues","volume":"55","author":"Arnold","year":"1994","journal-title":"Digestion"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0015","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/annonc\/10.suppl_2.S9","article-title":"Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract","volume":"10","author":"Solcia","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0020","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1093\/annonc\/10.suppl_4.S185","article-title":"Pancreatic endocrine tumours, immunotherapy and gene therapy: Chemotherapy and interferon therapy of endocrine tumours","volume":"10","author":"Veenhof","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00001622-199801000-00010","article-title":"Advances in chemotherapy and biotherapy of endocrine tumours","volume":"10","author":"Oberg","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0030","doi-asserted-by":"crossref","DOI":"10.1210\/jcem.86.2.7194","article-title":"Comparison of somatostatin analog and meta-iodobenzylguanidine (MIBG) radionuclides in the diagnosis and localisation of advanced neuro endocrine tumours","author":"Kaltsas","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1210\/edrv-12-4-450","article-title":"The role of somatostatin and its analogues in the diagnosis and treatment of tumours","volume":"12","author":"Lamberts","year":"1991","journal-title":"Endo Rev"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0040","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF00173043","article-title":"Radioiodinated meta-iodobenzylguanidine: A review of pharmacokinetics, drug interactions, cytotoxicity and dosimetry","volume":"21","author":"Wafelman","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0045","first-page":"96","article-title":"Radiolabeled meta-iodobenzylguanidine: Pharmacology and clinical studies","volume":"1","author":"Sisson","year":"1986","journal-title":"Am J Phys Imag"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0050","first-page":"308","article-title":"Radionuclide diagnosis and therapy of neural crest tumours using iodine-131 metaiodobenzylguanidine","volume":"28","author":"Hoefnagel","year":"1987","journal-title":"J Nucl Med."},{"issue":"Suppl 1\u20134","key":"10.1093\/annonc\/12.suppl_2.S47_bb0055","first-page":"150","article-title":"Ten years of experience with MIBG applications and the potential pf new radiolabeled peptides: A personal overview and concluding remarks","volume":"39","author":"Shapiro","year":"1995","journal-title":"Q J Nucl Med."},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0060","first-page":"1691","article-title":"Iodine-131 metaiodobenzylguanidine scintigraphy for carcinoid tumours","volume":"27","author":"Feldman","year":"1986","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0065","first-page":"334","article-title":"Role of 131Imetaiodobenzylguanidine therapy in medullary thyroid carcinoid","volume":"35","author":"Hoefnagel","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0070","series-title":"Somatostatin Receptor Scintigraphy. Nucl Med Ann","first-page":"1","author":"Krenning","year":"1995"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0075","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111InDTPA D Phel] and [123ityr3] octreotide: The Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med."},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0080","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/0959-8049(96)00241-9","article-title":"Combined diagnostic imaging with 131I-MIBG and 111In-pentetreotide in carcinoid tumours","volume":"32","author":"Taal","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0085","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/qjmed\/89.7.539","article-title":"Imaging secondary neuroendocrine tumours of the liver: Comparison of 1123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan)","volume":"89","author":"Ramage","year":"1996","journal-title":"Q J Med"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0090","first-page":"1121","article-title":"A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumours","volume":"33","author":"Bomanji","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0095","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/BF00173045","article-title":"Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours","volume":"21","author":"Hoefnagel","year":"1994","journal-title":"Eur J Nucl Med."},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0100","first-page":"1413","article-title":"In vivo somatostatin receptor imaging in medullary thyroid carcinoma","volume":"76","author":"Kwekkeboom","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0105","first-page":"336","article-title":"Nuclear medicine therapy for neuroblastoma","volume":"43","author":"Hoefnagel","year":"1999","journal-title":"Q J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0110","first-page":"177","article-title":"Procedings of the International workshop on \u2018The role of [131I]-metaiodobenzylguanidine in the treatment of neural crest tumours","volume":"35","author":"Troncone","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0115","first-page":"277","article-title":"Radiopharmaceutical therapy of malignant phaeochromocytoma with 131I-metaiodobenzylguanidine: Results from ten years of experience","volume":"35","author":"Shapiro","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0120","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant phaeochromocytoma with Iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients","volume":"20","author":"Loh","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0125","first-page":"1823","article-title":"131I-MIBG therapy of neural crest tumours (review)","volume":"17","author":"Troncone","year":"1997","journal-title":"Antic Res"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0130","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.1996.14.6.1829","article-title":"Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumours","author":"Taal","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0135","first-page":"1024","article-title":"Acute liver necrosis induced by iodine-131-MIBG in the treatment of metastatic carcinoid tumours","volume":"38","author":"Bongers","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0140","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2265.2001.01309.x","article-title":"Treatment of metastatic carcinoids, phaeochromocytomas, paragangliomas and medullary thyroid carcinoma of the thyroid with 131I-metaiodobenzylguanidine","author":"Mukherjee","year":"2001","journal-title":"Clin Endocrinol"},{"key":"10.1093\/annonc\/12.suppl_2.S47_bb0145","first-page":"368","article-title":"Ytrium-90 and Indium-111 labelling, receptor binding and biodistribution of [DOTA0,D-Phe1,Tyr3] octreotide, a promising somatostatin analogue for radionuclide therapy","volume":"24","author":"De Jonk","year":"1997","journal-title":"Eur J Nucl Med"},{"issue":"Suppl","key":"10.1093\/annonc\/12.suppl_2.S47_bb0150","first-page":"18","article-title":"DOTA-D-Phe(1)-Tyr(3)-octreotide (DOTATOC): A unique somatostatin receptor ligand for labelling with a variety of mettalic radionuclides","volume":"38","author":"Macke","year":"1997","journal-title":"J Nucl Med"},{"issue":"Suppl","key":"10.1093\/annonc\/12.suppl_2.S47_bb0155","first-page":"70","article-title":"Ytrium-90-DOTA-octreotide treatment of somatostatin receptor positive tumours","volume":"39","author":"Otte","year":"1998","journal-title":"J Nucl Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419544957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419544957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/suppl_2\/S47\/787418\/12-suppl_2-S47.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T11:58:53Z","timestamp":1589457533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419544957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":30,"alternative-id":["S0923753419544957"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/12.suppl_2.s47","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001]]}}}